421 related articles for article (PubMed ID: 29260852)
1. Targeting the Prion-like Aggregation of Mutant p53 to Combat Cancer.
Silva JL; Cino EA; Soares IN; Ferreira VF; A P de Oliveira G
Acc Chem Res; 2018 Jan; 51(1):181-190. PubMed ID: 29260852
[TBL] [Abstract][Full Text] [Related]
2. Aggregation tendencies in the p53 family are modulated by backbone hydrogen bonds.
Cino EA; Soares IN; Pedrote MM; de Oliveira GA; Silva JL
Sci Rep; 2016 Sep; 6():32535. PubMed ID: 27600721
[TBL] [Abstract][Full Text] [Related]
3. Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: implications for cancer.
Ano Bom AP; Rangel LP; Costa DC; de Oliveira GA; Sanches D; Braga CA; Gava LM; Ramos CH; Cepeda AO; Stumbo AC; De Moura Gallo CV; Cordeiro Y; Silva JL
J Biol Chem; 2012 Aug; 287(33):28152-62. PubMed ID: 22715097
[TBL] [Abstract][Full Text] [Related]
4. Amyloidogenicity of p53: a hidden link between protein misfolding and cancer.
Gong H; Yang X; Zhao Y; Petersen RB; Liu X; Liu Y; Huang K
Curr Protein Pept Sci; 2015; 16(2):135-46. PubMed ID: 25692950
[TBL] [Abstract][Full Text] [Related]
5. Propagation of aggregated p53: Cross-reaction and coaggregation vs. seeding.
Wang G; Fersht AR
Proc Natl Acad Sci U S A; 2015 Feb; 112(8):2443-8. PubMed ID: 25675527
[TBL] [Abstract][Full Text] [Related]
6. Expanding the prion concept to cancer biology: dominant-negative effect of aggregates of mutant p53 tumour suppressor.
Silva JL; Rangel LP; Costa DC; Cordeiro Y; De Moura Gallo CV
Biosci Rep; 2013 Jul; 33(4):. PubMed ID: 24003888
[TBL] [Abstract][Full Text] [Related]
7. Aggregation and Prion-Like Properties of Misfolded Tumor Suppressors: Is Cancer a Prion Disease?
Costa DC; de Oliveira GA; Cino EA; Soares IN; Rangel LP; Silva JL
Cold Spring Harb Perspect Biol; 2016 Oct; 8(10):. PubMed ID: 27549118
[TBL] [Abstract][Full Text] [Related]
8. Prion-like aggregation of mutant p53 in cancer.
Silva JL; De Moura Gallo CV; Costa DC; Rangel LP
Trends Biochem Sci; 2014 Jun; 39(6):260-7. PubMed ID: 24775734
[TBL] [Abstract][Full Text] [Related]
9. Biophysical characterization of p53 core domain aggregates.
Lima I; Navalkar A; Maji SK; Silva JL; de Oliveira GAP; Cino EA
Biochem J; 2020 Jan; 477(1):111-120. PubMed ID: 31841126
[TBL] [Abstract][Full Text] [Related]
10. Aggregation-primed molten globule conformers of the p53 core domain provide potential tools for studying p53C aggregation in cancer.
Pedrote MM; de Oliveira GAP; Felix AL; Mota MF; Marques MA; Soares IN; Iqbal A; Norberto DR; Gomes AMO; Gratton E; Cino EA; Silva JL
J Biol Chem; 2018 Jul; 293(29):11374-11387. PubMed ID: 29853637
[TBL] [Abstract][Full Text] [Related]
11. Pressure-temperature folding landscape in proteins involved in neurodegenerative diseases and cancer.
Cordeiro Y; Foguel D; Silva JL
Biophys Chem; 2013 Dec; 183():9-18. PubMed ID: 23849959
[TBL] [Abstract][Full Text] [Related]
12. The aggregation of mutant p53 produces prion-like properties in cancer.
Rangel LP; Costa DC; Vieira TC; Silva JL
Prion; 2014; 8(1):75-84. PubMed ID: 24509441
[TBL] [Abstract][Full Text] [Related]
13. Molecular dynamics study on the inhibition mechanisms of ReACp53 peptide for p53-R175H mutant aggregation.
Lei J; Cai M; Shen Y; Lin D; Deng X
Phys Chem Chem Phys; 2021 Oct; 23(40):23032-23041. PubMed ID: 34612239
[TBL] [Abstract][Full Text] [Related]
14. Modulation of p53 and prion protein aggregation by RNA.
Cordeiro Y; Vieira T; Kovachev PS; Sanyal S; Silva JL
Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):933-940. PubMed ID: 30826454
[TBL] [Abstract][Full Text] [Related]
15. The Status of p53 Oligomeric and Aggregation States in Cancer.
de Oliveira GAP; Petronilho EC; Pedrote MM; Marques MA; Vieira TCRG; Cino EA; Silva JL
Biomolecules; 2020 Apr; 10(4):. PubMed ID: 32260447
[TBL] [Abstract][Full Text] [Related]
16. p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells.
Rangel LP; Ferretti GDS; Costa CL; Andrade SMMV; Carvalho RS; Costa DCF; Silva JL
J Biol Chem; 2019 Mar; 294(10):3670-3682. PubMed ID: 30602570
[TBL] [Abstract][Full Text] [Related]
17. Effect of Mutation on an Aggregation-Prone Segment of p53: From Monomer to Dimer to Multimer.
Das A; Makarov DE
J Phys Chem B; 2016 Nov; 120(45):11665-11673. PubMed ID: 27775362
[TBL] [Abstract][Full Text] [Related]
18. Sulfated glycosaminoglycans mediate prion-like behavior of p53 aggregates.
Iwahashi N; Ikezaki M; Nishikawa T; Namba N; Ohgita T; Saito H; Ihara Y; Shimanouchi T; Ino K; Uchimura K; Nishitsuji K
Proc Natl Acad Sci U S A; 2020 Dec; 117(52):33225-33234. PubMed ID: 33318190
[TBL] [Abstract][Full Text] [Related]
19. Ligand binding and hydration in protein misfolding: insights from studies of prion and p53 tumor suppressor proteins.
Silva JL; Vieira TC; Gomes MP; Bom AP; Lima LM; Freitas MS; Ishimaru D; Cordeiro Y; Foguel D
Acc Chem Res; 2010 Feb; 43(2):271-9. PubMed ID: 19817406
[TBL] [Abstract][Full Text] [Related]
20. Backbone resonance assignments of the human p73 DNA binding domain.
Cino EA; Soares IN; Freitas MS; Silva JL
Biomol NMR Assign; 2016 Apr; 10(1):49-51. PubMed ID: 26294377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
